TN2011000283A1 - Human cgrp receptor binding proteins - Google Patents

Human cgrp receptor binding proteins

Info

Publication number: TN2011000283A1
Authority: TN; Tunisia
Prior art keywords: binding proteins; cgrp; receptor binding; cgrp receptor; human cgrp
Prior art date: 2008-12-23

Application number

TN2011000283A

Other languages

English (en)

Inventor

Thomas C Boone

David W Brankow

Jr Colin V Gegg

Shaw-Fen Sylvia Hu

Chadwick T King

Hsieng Sen Lu

Licheng Dhi

Cen Xu

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-23

Filing date

2011-06-01

Publication date

2012-12-17

2011-06-01 Application filed by Amgen Inc filed Critical Amgen Inc

2012-12-17 Publication of TN2011000283A1 publication Critical patent/TN2011000283A1/fr

Links

108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title abstract 2
102000014914 Carrier Proteins Human genes 0.000 title 1
108091008324 binding proteins Proteins 0.000 title 1
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 4
102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 4
102000025171 antigen binding proteins Human genes 0.000 abstract 3
108091000831 antigen binding proteins Proteins 0.000 abstract 3
208000019695 Migraine disease Diseases 0.000 abstract 1
206010027603 Migraine headaches Diseases 0.000 abstract 1
DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Diabetes (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Cell Biology (AREA)
Obesity (AREA)
Rheumatology (AREA)

TN2011000283A 2008-12-23 2011-06-01 Human cgrp receptor binding proteins TN2011000283A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20356908P	2008-12-23	2008-12-23
US26462209P	2009-11-25	2009-11-25
PCT/US2009/068858 WO2010075238A1 (fr)	2008-12-23	2009-12-18	Protéines de liaison au récepteur cgrp humain

Publications (1)

Publication Number	Publication Date
TN2011000283A1 true TN2011000283A1 (en)	2012-12-17

Family

ID=41718325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000283A TN2011000283A1 (en)	2008-12-23	2011-06-01	Human cgrp receptor binding proteins

Country Status (42)

Country	Link
US (7)	US9102731B2 (fr)
EP (4)	EP2379594B8 (fr)
JP (6)	JP5761805B2 (fr)
KR (4)	KR101853393B1 (fr)
CN (2)	CN102348722B (fr)
AR (1)	AR074857A1 (fr)
AU (2)	AU2009330175C1 (fr)
BR (2)	BR122020010360B1 (fr)
CA (1)	CA2746858C (fr)
CL (1)	CL2011001578A1 (fr)
CO (1)	CO6400232A2 (fr)
CR (1)	CR20110400A (fr)
CY (3)	CY1119465T1 (fr)
DK (3)	DK3569620T3 (fr)
EA (2)	EA201891500A3 (fr)
ES (3)	ES2643835T3 (fr)
FI (1)	FI3569620T3 (fr)
HR (3)	HRP20250807T1 (fr)
HU (4)	HUE034506T2 (fr)
IL (2)	IL213429A (fr)
JO (2)	JO3382B1 (fr)
LT (4)	LT3569620T (fr)
LU (1)	LUC00095I2 (fr)
MA (1)	MA32982B1 (fr)
ME (1)	ME03601B (fr)
MX (1)	MX2011006804A (fr)
MY (1)	MY180564A (fr)
NL (1)	NL300961I2 (fr)
NO (2)	NO2379594T3 (fr)
NZ (2)	NZ606090A (fr)
PE (1)	PE20120427A1 (fr)
PL (3)	PL3569620T3 (fr)
PT (3)	PT3184546T (fr)
RS (3)	RS56567B1 (fr)
SG (2)	SG172307A1 (fr)
SI (3)	SI3569620T1 (fr)
SM (1)	SMT201700504T1 (fr)
TN (1)	TN2011000283A1 (fr)
TW (4)	TW202241950A (fr)
UA (1)	UA108066C2 (fr)
WO (1)	WO2010075238A1 (fr)
ZA (1)	ZA201105418B (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007054809A2 (fr)	2005-11-14	2007-05-18	Rinat Neuroscience Corp.	Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
CA2705879A1 (fr) *	2007-11-21	2009-06-04	Amgen Inc.	Agents et epitopes de liaison a wise
EP2265287B1 (fr)	2008-03-04	2018-09-05	Teva Pharmaceuticals International GmbH	Procédés de traitement d'une douleur chronique
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2012002464A (es)	2009-08-28	2012-03-14	Rinat Neuroscience Corp	El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
RS66303B1 (sr)	2011-05-20	2025-01-31	H Lundbeck As	Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
EP3662932B1 (fr)	2011-05-20	2021-04-07	H. Lundbeck A/S	Compositions anti-cgrp et leur utilisation
EA033109B1 (ru)	2011-05-20	2019-08-30	Олдербайо Холдингз Ллк	Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
ES2770976T3 (es)	2013-03-15	2020-07-06	Amgen Inc	Anticuerpos PAC1 humanos
AU2014236867A1 (en)	2013-03-15	2015-09-24	Amgen Inc.	Methods and compositions relating to anti-CCR7 antigen binding proteins
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
GB2533173A (en)	2013-08-05	2016-06-15	Twist Bioscience Corp	De Novo synthesized gene libraries
EP3789064B1 (fr)	2013-10-24	2024-11-27	Amgen Inc.	Injecteur et procédé d'assemblage
US10758683B2 (en)	2013-10-24	2020-09-01	Amgen Inc.	Drug delivery system with temperature-sensitive control
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
BR112016021423A2 (pt) *	2014-03-21	2017-11-14	Teva Pharmaceuticals Int Gmbh	anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2945026C (fr)	2014-05-07	2023-10-10	Amgen Inc.	Auto-injecteur comprenant des elements de reduction de choc
EP4362039A3 (fr)	2014-06-03	2024-08-07	Amgen Inc.	Système d'administration de médicament contrôlable et procédé d'utilisation
JP6956631B2 (ja) *	2014-09-15	2021-11-02	アムジェンインコーポレイテッド	二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
MX2021014323A (es)	2014-10-14	2023-02-02	Amgen Inc	Dispositivo de inyección de fármaco con indicadores visuales y audibles.
ES2898469T3 (es)	2014-12-19	2022-03-07	Amgen Inc	Dispositivo de administración de medicamentos con sensor de proximidad
ES2785311T3 (es)	2014-12-19	2020-10-06	Amgen Inc	Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
AR103442A1 (es)	2015-01-16	2017-05-10	Juno Therapeutics Inc	Anticuerpos y receptores de antígenos quiméricos específicos de ror1
WO2016126882A1 (fr)	2015-02-04	2016-08-11	Twist Bioscience Corporation	Procédés et dispositifs pour assemblage de novo d'acide oligonucléique
CA2976935C (fr)	2015-02-17	2020-03-10	Amgen Inc.	Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
EP3981450A1 (fr)	2015-02-27	2022-04-13	Amgen, Inc	Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
WO2016172377A1 (fr)	2015-04-21	2016-10-27	Twist Bioscience Corporation	Dispositifs et procédés pour la synthèse de banques d'acides oligonucléiques
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
US10464983B2 (en)	2015-05-13	2019-11-05	The Board Of Regents Of The University Of Oklahoma	Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
WO2017039786A1 (fr)	2015-09-02	2017-03-09	Amgen Inc.	Adaptateur d'ensemble de seringue pour une seringue
AU2016324296A1 (en)	2015-09-18	2018-04-12	Twist Bioscience Corporation	Oligonucleic acid variant libraries and synthesis thereof
US11512347B2 (en)	2015-09-22	2022-11-29	Twist Bioscience Corporation	Flexible substrates for nucleic acid synthesis
ES2755717T3 (es)	2015-12-09	2020-04-23	Amgen Inc	Autoinyector con tapa de señalización
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
EP3411408B1 (fr)	2016-02-02	2021-12-08	Fred Hutchinson Cancer Research Center	Anticorps anti-ror1 et utilisations associées
EP4035711B1 (fr)	2016-03-15	2025-06-04	Amgen Inc.	Réduction de la probabilité de rupture de verre dans des dispositifs d'administration de médicament
CN109311977B (zh)	2016-04-15	2022-06-14	H.伦德贝克公司	人源化的抗pacap抗体及其用途
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es)	2016-05-13	2024-02-28	Amgen Inc	Conjunto de cubierta protectora de vial
WO2017200989A1 (fr)	2016-05-16	2017-11-23	Amgen Inc.	Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
EP3465124A1 (fr)	2016-06-03	2019-04-10	Amgen Inc.	Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments
US11285266B2 (en)	2016-07-01	2022-03-29	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
JP6871364B2 (ja)	2016-09-21	2021-05-12	ツイストバイオサイエンスコーポレーション	核酸に基づくデータ保存
CA3037661A1 (fr)	2016-09-23	2018-03-29	Teva Pharmaceuticals International Gmbh	Traitement de l'algie vasculaire de la face
KR20220031944A (ko)	2016-09-23	2022-03-14	테바 파마슈티컬스 인터내셔널 게엠베하	불응성 편두통의 치료
EP3532127A1 (fr)	2016-10-25	2019-09-04	Amgen Inc.	Injecteur porté sur le corps
US11993645B2 (en)	2017-01-11	2024-05-28	The Board Of Trustees Of The Leland Stanford Junior University	Compositions comprising R-Spondin (RSPO) surrogate molecules
US20190358411A1 (en)	2017-01-17	2019-11-28	Amgen Inc.	Injection devices and related methods of use and assembly
WO2018140821A1 (fr)	2017-01-26	2018-08-02	Surrozen, Inc.	Molécules d'amélioration de signal wnt spécifiques au tissu et leurs utilisations
JP7064501B2 (ja)	2017-02-17	2022-05-10	アムジエン・インコーポレーテツド	無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
CA3052204A1 (fr)	2017-02-17	2018-08-23	Amgen Inc.	Mecanisme d'insertion pour dispositif d'administration de medicament
EP4556433A3 (fr)	2017-02-22	2025-08-06	Twist Bioscience Corporation	Stockage de données à base d'acide nucléique
CA3055195A1 (fr)	2017-03-02	2018-09-07	Beth Israel Deaconess Medical Center, Inc.	Selection de patients atteints de cephalees presentant une reponse a des anticorps diriges contre un peptide lie au gene de la calcitonine
CA3050927A1 (fr)	2017-03-06	2018-09-13	Brian Stonecipher	Dispositif d'administration de medicaments dote d'une fonction de prevention d'activation
IL268478B2 (en)	2017-03-07	2023-10-01	Amgen Inc	Inserting a needle using super pressure
CA3052310A1 (fr)	2017-03-09	2018-09-13	Amgen Inc.	Mecanisme d'insertion pour dispositif d'administration de medicament
HUE063805T2 (hu)	2017-03-28	2024-01-28	Amgen Inc	Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
AU2018280054B2 (en)	2017-06-08	2023-07-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
MX2019014615A (es)	2017-06-08	2020-02-07	Amgen Inc	Dispositivo de administracion de farmacos accionado por par de torsion.
EP3641857A1 (fr)	2017-06-22	2020-04-29	Amgen Inc.	Réduction des impacts/chocs d'activation d'un dispositif
AU2018290302B2 (en)	2017-06-23	2024-02-29	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (es)	2017-07-14	2024-06-11	Amgen Inc	Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
JP7649105B2 (ja)	2017-07-21	2025-03-19	アムジエン・インコーポレーテツド	薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr)	2017-07-25	2020-06-03	Amgen Inc	Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en)	2017-07-25	2023-04-04	Amgen Inc.	Drug delivery device with gear module and related method of assembly
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (fr)	2017-08-18	2019-02-21	Amgen Inc.	Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
US11759565B2 (en)	2017-10-04	2023-09-19	Amgen Inc.	Flow adapter for drug delivery device
EP3691716B1 (fr)	2017-10-06	2023-11-29	Amgen Inc.	Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3694578B1 (fr)	2017-10-09	2025-09-24	Amgen Inc.	Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
GB2583590A (en)	2017-10-20	2020-11-04	Twist Bioscience Corp	Heated nanowells for polynucleotide synthesis
MA50528A (fr)	2017-11-03	2020-09-09	Amgen Inc	Systèmes et approches pour stériliser un dispositif d'administration de médicament
EP3707075A1 (fr)	2017-11-06	2020-09-16	Amgen Inc.	Ensembles de remplissage-finition et procédés associés
MA50553A (fr)	2017-11-06	2020-09-16	Amgen Inc	Dispositif d'administration de médicament avec détection de positionnement et de débit
MX2020004736A (es)	2017-11-10	2020-08-13	Amgen Inc	Embolos para dispositivos de administracion de farmacos.
WO2019099324A1 (fr)	2017-11-16	2019-05-23	Amgen Inc.	Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
SG11202006610YA (en)	2018-01-12	2020-08-28	Amgen Inc	Pac1 antibodies and uses thereof
JP2021519790A (ja)	2018-04-02	2021-08-12	アムジェンインコーポレイテッド	エレヌマブ組成物及びその使用
AU2019250882B2 (en)	2018-04-12	2025-10-16	Amgen Inc.	Methods for making stable protein compositions
EP3814497A4 (fr)	2018-05-18	2022-03-02	Twist Bioscience Corporation	Polynucléotides, réactifs, et procédés d'hybridation d'acides nucléiques
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
AU2019301633A1 (en)	2018-07-09	2021-01-28	Surrozen Operating, Inc.	Tissue-specific Wnt signal enhancing molecules and uses
CN112469454B (zh)	2018-07-24	2024-01-26	安进公司	用于施用药物的输送装置
WO2020023336A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
WO2020023220A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
MA53375A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
US12109389B2 (en)	2018-07-31	2024-10-08	Amgen Inc.	Fluid path assembly for a drug delivery device
CA3106452A1 (fr)	2018-09-24	2020-04-02	Amgen Inc.	Systemes et procedes de dosage interventionnel
EP3856283A1 (fr)	2018-09-28	2021-08-04	Amgen Inc.	Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
WO2020072577A1 (fr)	2018-10-02	2020-04-09	Amgen Inc.	Systèmes d'injection pour administration de médicament avec transmission de force interne
EP3860686A1 (fr)	2018-10-05	2021-08-11	Amgen Inc.	Dispositif d'administration de médicament ayant un indicateur de dose
AR116703A1 (es)	2018-10-15	2021-06-02	Amgen Inc	Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos
EA202191037A1 (ru)	2018-10-15	2021-08-05	Эмджен Инк.	Устройство доставки лекарственного средства, имеющее демпферный механизм
MA54048A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
IL281908B2 (en)	2018-11-01	2025-06-01	Amgen Inc	Drug delivery devices with partial drug delivery member retraction
CA3124980A1 (fr)	2018-12-26	2020-07-02	Twist Bioscience Corporation	Synthese de novo polynucleotidique hautement precise
CN113227140A (zh)	2019-01-08	2021-08-06	H.隆德贝克有限公司	使用抗cgrp抗体急性治疗和快速治疗头痛
WO2020176678A1 (fr) *	2019-02-26	2020-09-03	Twist Bioscience Corporation	Banques de variants d'acides nucléiques pour le récepteur glp1
MX2021012557A (es)	2019-04-24	2021-11-12	Amgen Inc	Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
WO2020239014A1 (fr) *	2019-05-30	2020-12-03	山东博安生物技术有限公司	Anticorps anti cgrp et son utilisation
JP7756001B2 (ja)	2019-06-28	2025-10-17	アムジエン・インコーポレーテツド	抗ｃｇｒｐ受容体／抗ｐａｃ１受容体二重特異性抗原結合タンパク質
CA3148261A1 (fr)	2019-08-23	2021-03-04	Amgen Inc.	Dispositif d'administration de medicament dote de composants configurables de mise en prise de protection d'aiguille et methodes associees
CA3155630A1 (fr)	2019-09-23	2021-04-01	Twist Bioscience Corporation	Bibliotheques d'acides nucleiques variants pour des anticorps a domaine unique
EP4464827A3 (fr)	2019-09-23	2025-02-26	Twist Bioscience Corporation	Banques d'acides nucléiques variants pour crth2
BR102020007149A8 (pt)	2020-04-06	2023-09-26	H Lundbeck As	Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
KR20230109668A (ko)	2020-11-16	2023-07-20	서로젠 오퍼레이팅, 인크.	간-특이적 Wnt 신호 증강 분자 및 그의 용도
EP4301362A1 (fr)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Traitement et/ou réduction de l'apparition de migraine
EP4341161A1 (fr)	2021-05-21	2024-03-27	Amgen Inc.	Procédé d?optimisation d?une recette de remplissage pour un récipient de médicament
WO2023026205A1 (fr)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Traitement préventif de la migraine
WO2023215829A1 (fr) *	2022-05-05	2023-11-09	Amgen Inc.	Hétéromultimère se liant à dll3 et cd3
TW202432600A (zh)	2022-11-07	2024-08-16	美商安進公司	用於治療肥胖症之方法
WO2025226754A1 (fr)	2024-04-23	2025-10-30	Amgen Inc.	Procédé de prédiction de l'osmolalité de solutions protéiques
CN118459595A (zh) *	2024-05-21	2024-08-09	杭州百懿生物药业有限公司	特异性结合cgrp受体的抗体分子及其用途

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
JPS63502716A (ja)	1986-03-07	1988-10-13	マサチューセッツ・インステチュート・オブ・テクノロジー	糖タンパク安定性の強化方法
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
AU643427B2 (en)	1988-10-31	1993-11-18	Immunex Corporation	Interleukin-4 receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JPH02229119A (ja)	1989-02-28	1990-09-11	Toyo Jozo Co Ltd	動脈硬化予防および治療剤
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
WO1991018982A1 (fr)	1990-06-05	1991-12-12	Immunex Corporation	Recepteurs de l'interleukine-1 de type ii
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DK0575319T3 (da)	1991-03-11	2000-07-10	Univ Georgia Res Found	Kloning og ekspression af Renilla-luciferase
CA2111348A1 (fr)	1991-06-14	1992-12-23	John S. Logan	Production d'hemoglobine humaine dans des porcs transgeniques
CA2113113A1 (fr)	1991-07-08	1993-01-21	Simon W. Kantor	Copolymere sequence a cristaux liquides thermotropiques
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
DK0640131T3 (da) *	1992-03-17	1999-11-01	Novartis Ag	Gensplejsere antistoffer
JPH07509137A (ja)	1992-07-24	1995-10-12	セル　ジェネシス，インク．	異種抗体の生産
DE69332981T2 (de)	1992-10-23	2004-05-19	Immunex Corp., Seattle	Methoden zur herstellung löslicher, oligomerer proteine
US5766880A (en)	1992-10-27	1998-06-16	Queen's University At Kingston	Isolated nucleic acid molecules encoding multidrug resistance proteins
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
WO1995007463A1 (fr)	1993-09-10	1995-03-16	The Trustees Of Columbia University In The City Of New York	Methodes d'utilisation de proteines fluorescentes vertes
WO1995021191A1 (fr)	1994-02-04	1995-08-10	William Ward	Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
WO1996003993A2 (fr)	1994-08-05	1996-02-15	The Rockefeller University	Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t
DE69433747D1 (de) *	1994-08-16	2004-06-03	Human Genome Sciences Inc	Calcitoninrezeptor
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
ATE390933T1 (de)	1995-04-27	2008-04-15	Amgen Fremont Inc	Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
WO1998003534A1 (fr)	1996-07-23	1998-01-29	Smithkline Beecham Corporation	Facteur composant du recepteur du peptide apparente au gene de la calcitonine (houdc44)
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6255455B1 (en) *	1996-10-11	2001-07-03	The Trustees Of The University Of Pennsylvania	Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
DK1500329T3 (da)	1996-12-03	2012-07-09	Amgen Fremont Inc	Humane antistoffer, der specifikt binder TNF-alfa
US6458547B1 (en)	1996-12-12	2002-10-01	Prolume, Ltd.	Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (fr)	1997-01-31	1998-07-31	Stephen William Watson Michnick	Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
DE19732944A1 (de)	1997-07-31	1999-02-04	Thomae Gmbh Dr K	Peptidische CGRP-Antagonisten
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
US6232107B1 (en)	1998-03-27	2001-05-15	Bruce J. Bryan	Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6268474B1 (en)	1998-04-30	2001-07-31	Creighton University	Peptide antagonists of CGRP-receptor superfamily and methods of use
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
WO2000009560A2 (fr)	1998-08-17	2000-02-24	Abgenix, Inc.	Production de molecules modifiees avec demi-vie serique prolongee
WO2001040794A1 (fr) *	1999-12-02	2001-06-07	Myriad Genetics, Inc.	Interactions entre proteines
US20020090646A1 (en)	2000-05-03	2002-07-11	Amgen Inc.	Calcitonin-related molecules
FR2821080B1 (fr)	2001-02-20	2003-12-19	Sanofi Synthelabo	Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
AU2002329540A1 (en) *	2001-06-20	2003-01-02	Morphosys Ag	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2461917C (fr)	2001-09-27	2012-01-17	Merck & Co., Inc.	Molecules d'adn isolees codant un recepteur humanise du peptide lie au gene de la calcitonine, animaux transgeniques non humains associes et methodes d'analyse
US7658924B2 (en) *	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
EP2338910B1 (fr) *	2002-01-18	2015-07-08	ZymoGenetics, Inc.	Multimères Zcytor17 du récepteur de la cytokine
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20040110170A1 (en) *	2002-05-18	2004-06-10	The Regents Of The University Of California	Cloning and characterization of calcitonin gene related peptide receptors
US20070071744A1 (en)	2002-06-07	2007-03-29	Gotz Munch	Agents which bind to epitopes of glycoprotein VI
AU2003260944B2 (en) *	2002-08-12	2009-05-14	Actavis Group Hf.	Use of CGRP antagonist compounds for treatment of psoriasis
US20040176577A1 (en) *	2002-09-10	2004-09-09	Eva Rojer	Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (fr)	2003-04-29	2004-11-11	Bayer Healthcare Ag	Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
RU2378285C2 (ru)	2004-02-11	2010-01-10	Амилин Фармасьютикалз, Инк.	Гибридные полипептиды с селектируемыми свойствами
US7423128B2 (en) *	2004-11-03	2008-09-09	Amgen Fremont Inc.	Anti-properdin antibodies, and methods for making and using same
ATE521638T1 (de) *	2004-12-21	2011-09-15	Medimmune Ltd	Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
EP1900374B1 (fr)	2005-06-16	2014-03-12	Takayuki Shindo	Agent angiogénétique contenant de l adrénoméduline comme principe actif
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
WO2007054809A2 (fr)	2005-11-14	2007-05-18	Rinat Neuroscience Corp.	Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
WO2007076336A1 (fr) *	2005-12-22	2007-07-05	Eli Lilly And Company	Traitement de la migraine avec des anticorps anti-cgrp
RU2009107277A (ru) *	2006-08-03	2010-09-10	Астразенека Аб (Se)	АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
GB0708002D0 (en) *	2007-04-25	2007-06-06	Univ Sheffield	Antibodies
ES2584907T3 (es)	2008-03-04	2016-09-30	Labrys Biologics Inc.	Métodos para tratamiento del dolor inflamatorio
FR2934597B1 (fr) *	2008-07-31	2013-04-19	Univ Aix Marseille Ii	Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2012002464A (es)	2009-08-28	2012-03-14	Rinat Neuroscience Corp	El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
JP5782185B2 (ja)	2012-06-01	2015-09-24	日本電信電話株式会社	パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof
JP6956631B2 (ja) *	2014-09-15	2021-11-02	アムジェンインコーポレイテッド	二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
JOP20200116A1 (ar) *	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
US11385238B2 (en) *	2017-06-30	2022-07-12	Amgen Inc.	Methods of protein clips recovery
JP2021519790A (ja) *	2018-04-02	2021-08-12	アムジェンインコーポレイテッド	エレヌマブ組成物及びその使用

2009
- 2009-12-02 JO JOP/2009/0461A patent/JO3382B1/ar active
- 2009-12-18 BR BR122020010360-4A patent/BR122020010360B1/pt active IP Right Grant
- 2009-12-18 RS RS20171121A patent/RS56567B1/sr unknown
- 2009-12-18 CN CN200980157606.3A patent/CN102348722B/zh active Active
- 2009-12-18 US US12/642,711 patent/US9102731B2/en active Active
- 2009-12-18 HU HUE09775072A patent/HUE034506T2/en unknown
- 2009-12-18 KR KR1020177013822A patent/KR101853393B1/ko active Active
- 2009-12-18 PT PT16199717T patent/PT3184546T/pt unknown
- 2009-12-18 EA EA201891500A patent/EA201891500A3/ru unknown
- 2009-12-18 SG SG2011045556A patent/SG172307A1/en unknown
- 2009-12-18 SG SG10201401879TA patent/SG10201401879TA/en unknown
- 2009-12-18 RS RS20250696A patent/RS67071B1/sr unknown
- 2009-12-18 HU HUE16199717A patent/HUE045966T2/hu unknown
- 2009-12-18 DK DK19181187.6T patent/DK3569620T3/da active
- 2009-12-18 EP EP09775072.3A patent/EP2379594B8/fr active Active
- 2009-12-18 EP EP19181187.6A patent/EP3569620B1/fr active Active
- 2009-12-18 RS RSP20191122 patent/RS59343B1/sr unknown
- 2009-12-18 WO PCT/US2009/068858 patent/WO2010075238A1/fr not_active Ceased
- 2009-12-18 LT LTEP19181187.6T patent/LT3569620T/lt unknown
- 2009-12-18 UA UAA201109219A patent/UA108066C2/ru unknown
- 2009-12-18 FI FIEP19181187.6T patent/FI3569620T3/fi active
- 2009-12-18 HR HRP20250807TT patent/HRP20250807T1/hr unknown
- 2009-12-18 SM SM20170504T patent/SMT201700504T1/it unknown
- 2009-12-18 AU AU2009330175A patent/AU2009330175C1/en active Active
- 2009-12-18 SI SI200932214T patent/SI3569620T1/sl unknown
- 2009-12-18 EA EA201100892A patent/EA031320B1/ru active Protection Beyond IP Right Term
- 2009-12-18 PT PT191811876T patent/PT3569620T/pt unknown
- 2009-12-18 KR KR1020187011418A patent/KR20180043850A/ko not_active Ceased
- 2009-12-18 EP EP25165937.1A patent/EP4585264A3/fr active Pending
- 2009-12-18 PT PT97750723T patent/PT2379594T/pt unknown
- 2009-12-18 JP JP2011543606A patent/JP5761805B2/ja active Active
- 2009-12-18 MX MX2011006804A patent/MX2011006804A/es active IP Right Grant
- 2009-12-18 ES ES09775072.3T patent/ES2643835T3/es active Active
- 2009-12-18 LT LTEP09775072.3T patent/LT2379594T/lt unknown
- 2009-12-18 MA MA34035A patent/MA32982B1/fr unknown
- 2009-12-18 NO NO09775072A patent/NO2379594T3/no unknown
- 2009-12-18 ES ES19181187T patent/ES3036151T3/es active Active
- 2009-12-18 CA CA2746858A patent/CA2746858C/fr active Active
- 2009-12-18 DK DK09775072.3T patent/DK2379594T3/en active
- 2009-12-18 DK DK16199717.6T patent/DK3184546T3/da active
- 2009-12-18 KR KR1020197013698A patent/KR20190054181A/ko not_active Ceased
- 2009-12-18 ES ES16199717T patent/ES2746571T3/es active Active
- 2009-12-18 PL PL19181187.6T patent/PL3569620T3/pl unknown
- 2009-12-18 NZ NZ606090A patent/NZ606090A/en unknown
- 2009-12-18 CN CN201610333096.2A patent/CN106084045B/zh active Active
- 2009-12-18 KR KR1020117017235A patent/KR101740615B1/ko active Active
- 2009-12-18 PL PL16199717T patent/PL3184546T3/pl unknown
- 2009-12-18 ME MEP-2019-240A patent/ME03601B/fr unknown
- 2009-12-18 LT LTEP16199717.6T patent/LT3184546T/lt unknown
- 2009-12-18 BR BRPI0922505-6A patent/BRPI0922505B1/pt active IP Right Grant
- 2009-12-18 PE PE2011001269A patent/PE20120427A1/es active IP Right Grant
- 2009-12-18 HU HUE19181187A patent/HUE072123T2/hu unknown
- 2009-12-18 SI SI200931989T patent/SI3184546T1/sl unknown
- 2009-12-18 SI SI200931756T patent/SI2379594T1/sl unknown
- 2009-12-18 PL PL09775072T patent/PL2379594T3/pl unknown
- 2009-12-18 EP EP16199717.6A patent/EP3184546B8/fr active Active
- 2009-12-18 MY MYPI2011002908A patent/MY180564A/en unknown
- 2009-12-18 HR HRP20171690TT patent/HRP20171690T1/hr unknown
- 2009-12-18 NZ NZ623541A patent/NZ623541A/en unknown
- 2009-12-22 AR ARP090105053A patent/AR074857A1/es active IP Right Grant
- 2009-12-22 TW TW110149087A patent/TW202241950A/zh unknown
- 2009-12-22 TW TW098144377A patent/TWI574697B/zh active
- 2009-12-22 TW TW108136419A patent/TWI754176B/zh active
- 2009-12-22 TW TW105134382A patent/TWI688403B/zh active
2011
- 2011-06-01 TN TN2011000283A patent/TN2011000283A1/fr unknown
- 2011-06-06 IL IL213429A patent/IL213429A/en active Protection Beyond IP Right Term
- 2011-06-23 CL CL2011001578A patent/CL2011001578A1/es unknown
- 2011-07-15 CO CO11088995A patent/CO6400232A2/es active IP Right Grant
- 2011-07-22 ZA ZA2011/05418A patent/ZA201105418B/en unknown
- 2011-07-22 CR CR20110400A patent/CR20110400A/es unknown
2012
- 2012-09-12 US US13/612,615 patent/US20130071410A1/en not_active Abandoned
2013
- 2013-04-10 AU AU2013205271A patent/AU2013205271C1/en active Active
2014
- 2014-08-12 JP JP2014164088A patent/JP6261132B2/ja active Active
2015
- 2015-06-26 US US14/752,493 patent/US9862771B2/en active Active
- 2015-11-09 JP JP2015219157A patent/JP2016026224A/ja not_active Withdrawn
2016
- 2016-01-26 IL IL243784A patent/IL243784A/en active IP Right Grant
2017
- 2017-08-28 CY CY20171100901T patent/CY1119465T1/el unknown
- 2017-11-28 US US15/824,827 patent/US20180142029A1/en not_active Abandoned
2018
- 2018-12-04 CY CY2018032C patent/CY2018032I2/el unknown
- 2018-12-10 HU HUS1800047C patent/HUS1800047I1/hu unknown
- 2018-12-12 NL NL300961C patent/NL300961I2/nl unknown
- 2018-12-14 LT LTPA2018017C patent/LTC2379594I2/lt unknown
- 2018-12-17 NO NO2018042C patent/NO2018042I1/no unknown
- 2018-12-20 LU LU00095C patent/LUC00095I2/fr unknown
- 2018-12-28 JP JP2018246704A patent/JP2019062907A/ja not_active Withdrawn
2019
- 2019-02-07 JO JOP/2019/0017A patent/JOP20190017B1/ar active
- 2019-07-25 HR HRP20191341TT patent/HRP20191341T8/hr unknown
- 2019-09-19 CY CY20191100989T patent/CY1122658T1/el unknown
2020
- 2020-11-27 JP JP2020196689A patent/JP2021036912A/ja not_active Withdrawn
- 2020-12-03 US US17/111,442 patent/US12122841B2/en active Active
- 2020-12-03 US US17/111,453 patent/US12134652B2/en active Active
2023
- 2023-06-21 JP JP2023101810A patent/JP7584577B2/ja active Active
2024
- 2024-10-02 US US18/904,787 patent/US20250129172A1/en active Pending

Also Published As

Publication number	Publication date
EP3184546B1 (fr)	2019-07-17
JP2019062907A (ja)	2019-04-25
JP2014210815A (ja)	2014-11-13
EP3569620B1 (fr)	2025-05-07
LT2379594T (lt)	2017-11-27
LTPA2018017I1 (lt)	2019-01-10
EP3569620A1 (fr)	2019-11-20
LT3569620T (lt)	2025-07-25
CN106084045B (zh)	2020-02-11
KR20190054181A (ko)	2019-05-21
ES3036151T3 (en)	2025-09-15
CY1119465T1 (el)	2018-03-07
JP2012513214A (ja)	2012-06-14
EA031320B1 (ru)	2018-12-28
IL243784A0 (en)	2016-04-21
KR101853393B1 (ko)	2018-05-02
CY2018032I1 (el)	2019-07-10
US20210179722A1 (en)	2021-06-17
HRP20191341T8 (hr)	2020-02-07
RS59343B1 (sr)	2019-10-31
TW202026312A (zh)	2020-07-16
US20210179723A1 (en)	2021-06-17
PE20120427A1 (es)	2012-05-13
DK3184546T3 (da)	2019-09-30
NO2018042I1 (no)	2018-12-17
AR074857A1 (es)	2011-02-16
CY1122658T1 (el)	2021-03-12
NZ606090A (en)	2014-08-29
HRP20191341T1 (hr)	2019-10-18
SI2379594T1 (sl)	2017-12-29
AU2009330175B2 (en)	2014-01-16
WO2010075238A1 (fr)	2010-07-01
US20180142029A1 (en)	2018-05-24
PT3184546T (pt)	2019-09-16
US9862771B2 (en)	2018-01-09
US20250129172A1 (en)	2025-04-24
EP3184546B8 (fr)	2019-10-30
PL3184546T3 (pl)	2019-12-31
SG10201401879TA (en)	2014-06-27
CO6400232A2 (es)	2012-03-15
EP4585264A3 (fr)	2025-10-29
PL3569620T3 (pl)	2025-10-20
ES2746571T3 (es)	2020-03-06
PT2379594T (pt)	2017-11-16
TW201703796A (zh)	2017-02-01
ES2643835T3 (es)	2017-11-24
AU2013205271A1 (en)	2013-05-02
IL213429A (en)	2016-02-29
JO3382B1 (ar)	2019-03-13
AU2013205271B2 (en)	2016-07-14
NL300961I2 (nl)	2019-01-15
IL243784A (en)	2016-11-30
US20100172895A1 (en)	2010-07-08
JP2016026224A (ja)	2016-02-12
JP2021036912A (ja)	2021-03-11
NO2379594T3 (fr)	2018-01-06
LUC00095I2 (fr)	2019-12-24
US9102731B2 (en)	2015-08-11
MA32982B1 (fr)	2012-01-02
KR101740615B1 (ko)	2017-05-26
ME03601B (fr)	2020-07-20
MY180564A (en)	2020-12-02
EP3184546A1 (fr)	2017-06-28
TWI754176B (zh)	2022-02-01
DK3569620T3 (da)	2025-08-04
LTC2379594I2 (lt)	2020-04-10
US20150376286A1 (en)	2015-12-31
DK2379594T3 (en)	2017-10-30
BR122020010360B1 (pt)	2022-08-16
SI3569620T1 (sl)	2025-08-29
UA108066C2 (uk)	2015-03-25
CY2018032I2 (el)	2019-07-10
JP5761805B2 (ja)	2015-08-12
US20130071410A1 (en)	2013-03-21
HRP20171690T1 (hr)	2017-12-15
AU2009330175C1 (en)	2018-10-04
US12122841B2 (en)	2024-10-22
TW201032823A (en)	2010-09-16
HRP20250807T1 (hr)	2025-09-12
EP2379594B8 (fr)	2020-12-30
CN106084045A (zh)	2016-11-09
CN102348722A (zh)	2012-02-08
AU2013205271C1 (en)	2018-10-04
NZ623541A (en)	2015-12-24
EP2379594A1 (fr)	2011-10-26
KR20180043850A (ko)	2018-04-30
SI3184546T1 (sl)	2019-09-30
US12134652B2 (en)	2024-11-05
CA2746858C (fr)	2017-10-03
HUE072123T2 (hu)	2025-10-28
LUC00095I1 (fr)	2018-12-28
EA201100892A1 (ru)	2012-01-30
ZA201105418B (en)	2012-02-29
CN102348722B (zh)	2016-06-08
JP7584577B2 (ja)	2024-11-15
AU2009330175A1 (en)	2011-06-23
CR20110400A (es)	2011-10-12
EA201891500A3 (ru)	2019-03-29
EA201891500A2 (ru)	2018-11-30
EP2379594B1 (fr)	2017-08-09
MX2011006804A (es)	2011-09-27
HUE045966T2 (hu)	2020-01-28
IL213429A0 (en)	2011-07-31
LT3184546T (lt)	2019-09-10
JOP20190017B1 (ar)	2023-03-28
HUS1800047I1 (hu)	2018-12-28
EP4585264A2 (fr)	2025-07-16
HUE034506T2 (en)	2018-02-28
CL2011001578A1 (es)	2012-01-20
TWI688403B (zh)	2020-03-21
TW202241950A (zh)	2022-11-01
JP2023116783A (ja)	2023-08-22
SG172307A1 (en)	2011-07-28
PL2379594T3 (pl)	2018-01-31
BRPI0922505A2 (pt)	2016-07-05
TWI574697B (zh)	2017-03-21
KR20170061182A (ko)	2017-06-02
RS67071B1 (sr)	2025-08-29
PT3569620T (pt)	2025-07-21
BRPI0922505B1 (pt)	2021-08-03
RS56567B1 (sr)	2018-02-28
JP6261132B2 (ja)	2018-01-17
JOP20190017A1 (ar)	2017-06-16
KR20110106409A (ko)	2011-09-28
CA2746858A1 (fr)	2010-07-01
SMT201700504T1 (it)	2018-01-11
FI3569620T3 (fi)	2025-07-15

Publication	Publication Date	Title
JOP20190017B1 (ar)	2023-03-28	أجسام مضادة ترتبط مع مستقبل cgrp بشري
TN2012000167A1 (en)	2013-12-12	Human il-23 antigen binding proteins
EA201001223A1 (ru)	2011-06-30	Стабилизированные белковые композиции
MX351502B (es)	2017-10-18	Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX2010008874A (es)	2010-09-22	Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
MY160590A (en)	2017-03-15	Cd127 binding proteins
NZ583282A (en)	2012-09-28	Human c-fms antigen binding proteins
PH12014502527A1 (en)	2015-01-12	St2 antigen binding proteins
TN2012000479A1 (en)	2014-04-01	Fibronectin based scaffold domain proteins that bind pcsk9
PH12015500806A1 (en)	2015-12-02	Binding molecules to the human ox40 receptor
NZ593905A (en)	2013-03-28	Il-1 binding proteins
GEP20166454B (en)	2016-04-11	Sclerostin binding agents
MX345226B (es)	2017-01-20	Formulaciones de moleculas de union a antigeno de dominio sencillo.
UA107921C2 (en)	2015-03-10	Variants of polypeptide of receptor ivr activin and their use
MY150400A (en)	2014-01-15	Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008151819A3 (fr)	2009-04-09	Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
HK1198832A1 (en)	2015-06-12	Fn14 binding proteins and uses thereof
UA97414C2 (ru)	2012-02-10	Выделенное человеческое антитело, связывающееся с gm-csf